Related Experiment Video
Updated: May 16, 2025

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
Published on: March 6, 2018
Arsenic exposure provoked prostatic PANoptosis by inducing mitochondrial dysfunction in mice and WPMY-1 cells
Yiping Yang1, Xianglan Chen1, Longxin Deng2
1Department of Experimental Research, Guangxi Medical University Cancer Hospital, Nanning 530021, China.
Abstract:
Inorganic arsenic, a widespread environmental toxicant, significantly contributes to prostate injury. However, the exact cellular mechanisms remain unclear. This study explored the involvement of pyroptosis, apoptosis, and necroptosis (PANoptosis), and their interconnections in arsenic-induced prostate injury. Herein, by employing in vitro (WPMY-1 cells exposed to arsenic for 48 h with or without reactive oxygen species (ROS) and mitochondrial ROS scavenger treatments) and in vivo (C57BL/6 mice were orally gavaged with arsenic and/or N-acetylcysteine for 90 consecutive days) models of arsenic-induced prostate injury and intervention, we demonstrated that sodium arsenite (NaAsO2) triggered mitochondrial damage-activated PANoptosis via the Bax/Bcl-xL/caspase-3/Gasdermin E (GSDME) pathway and the Z-DNA binding protein 1/receptor-interacting protein kinases 1 (RIPK1)/RIPK3/mixed lineage kinase domain-like protein (MLKL) signaling pathway. Notably, treatment with NaAsO2, GSDME, or MLKL knockdown in WPMY-1 cells increased the phenotype of PANoptosis. Mechanistically, the GSDME-N, GSDMD-N, p-MLKL, and cleaved caspase-3 protein levels were increased (1.4-, 2.67-, 3.51-, and 2.16-fold, respectively) in NaAsO2-treated GSDME knockdown WPMY-1 cells, whereas GSDME-N and cleaved caspase-3 protein levels were increased (1.30- and 1.21-fold, respectively) in NaAsO2-treated MLKL knockdown WPMY-1 cells. Our study highlights the crucial role of mitochondrial dysfunction in the initiation of PANoptosis during arsenic-induced prostate injury. Furthermore, we provide novel insights into the connections between apoptosis, pyroptosis, and necroptosis, indicating that GSDME and MLKL proteins may act as crucial regulators and potential therapeutic targets for arsenic-induced PANoptosis.
Insights
Inorganic arsenic exposure triggers cell death pathways, known as PANoptosis, in prostate injury. Mitochondrial dysfunction initiates this process, with GSDME and MLKL emerging as potential therapeutic targets.
Area of Science:
- Toxicology
- Cellular Biology
- Molecular Mechanisms of Cell Death
Background:
- Inorganic arsenic is a known environmental toxicant that causes prostate injury.
- The precise cellular mechanisms underlying arsenic-induced prostate injury are not fully understood.
- PANoptosis, encompassing pyroptosis, apoptosis, and necroptosis, is an emerging cell death pathway.
Purpose of the Study:
- To investigate the role of PANoptosis in arsenic-induced prostate injury.
- To elucidate the interconnections between pyroptosis, apoptosis, and necroptosis in this context.
- To identify potential molecular targets for mitigating arsenic toxicity in the prostate.
Main Methods:
- In vitro studies using WPMY-1 cells exposed to sodium arsenite (NaAsO2), with and without reactive oxygen species (ROS) scavengers.
- In vivo studies using C57BL/6 mice treated with NaAsO2 and/or N-acetylcysteine.
- Analysis of key proteins involved in apoptosis, pyroptosis, and necroptosis signaling pathways, including GSDME and MLKL.
Main Results:
- Sodium arsenite induced mitochondrial damage-activated PANoptosis via the Bax/Bcl-xL/caspase-3/Gasdermin E (GSDME) and RIPK1/RIPK3/MLKL pathways.
- Knockdown of GSDME or MLKL modulated PANoptosis phenotypes in NaAsO2-treated cells.
- Mitochondrial dysfunction was identified as a critical initiator of PANoptosis in arsenic-induced prostate injury.
Conclusions:
- Mitochondrial dysfunction plays a pivotal role in initiating PANoptosis during arsenic-induced prostate injury.
- GSDME and MLKL are crucial regulators of PANoptosis in this model.
- GSDME and MLKL represent potential therapeutic targets for arsenic-induced prostate injury.

